Since hepatic GLP‐1 resistance may develop in patients with T2DM and NAFLD,207, 208 a GLP‐1 synthesizer like butyrate may work better than exogenous GLP‐1 or GLP‐1 agonists. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.